Grifols SA operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Grifols SA with three other
pharmaceutical manufacturers in Europe:
sales of 241.48 billion Russian Rubles [US$4.18 billion]
of which 81%
Lonza Group AG
(4.13 billion Swiss Francs [US$4.24 billion]
of which 54%
was Specialty Ingredients), and
based in Belgium
(4.18 billion Euro [US$4.96 billion]
of which 100%
Grifols SA reported sales of 4.05 billion Euro (US$4.80 billion)
December of 2016.
increase of 2.9%
versus 2015, when the company's sales were 3.93 billion Euro.
Sales at Grifols SA have increased during each of the previous five years
(and since 2011, sales have increased a total of 126%).
Sales of Bioscience saw an increase
that was more than double the company's growth rate: sales were up
6.5% in 2016, from
3.03 billion Euro to 3.23 billion Euro.
Not all segments of Grifols SA experienced an increase in sales in 2016:
sales of Others/raw Materials fell 48.6% to 58.99 million Euro.
(However, this segment's sales were only a very small portion of the company's overall sales).
Grifols SA also experienced decreases in sales in
Diagnostics (down 4.0% to 663.98 million Euro)